Last reviewed · How we verify

NCT06011460: CloGD

Observation of Clozapine Treatment Safety in Bipolar Disorder.

ENROLLING BY INVITATION Last updated 25 August 2023
What this trial tests

trial testing Clozapine in Bipolar Disorder in 30 participants. Enrolling by invitation.

Timeline
23 February 2023
Primary endpoint
31 December 2024
30 June 2027

Quick facts

Lead sponsorMedical University of Gdansk
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment30
Start date23 February 2023
Primary completion31 December 2024
Estimated completion30 June 2027
Sites1 location across Poland

Drugs / interventions tested

Conditions studied

Sponsor

Medical University of Gdansk

Who can join

Adults 18 to 65, any sex, with Bipolar Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the registry is to record incidence of adverse events during treatment with clozapine in patients suffering from bipolar disorder.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Clozapine

Trials testing the same drug.

Other recruiting trials for Bipolar Disorder

Currently open trials in the same condition.

Other Medical University of Gdansk trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06011460.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing